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a b s t r a c t
Ursolic acid is a pentacyclic triterpenoid that possesses several biological and neuropharmacological
effects including antidepressant-like activity. Anxiety disorders represent common and disability
psychiatric conditions that are often associated with depressive symptoms. This work investigated the
anxiolytic-like effects of ursolic acid administration in different behavioral paradigms that evaluate
anxiety in mice: open ﬁeld test, elevated plus maze test, light/dark box test and marble burying test. To
this end, mice were administered with ursolic acid (0.1, 1 and 10 mg/kg, p.o.) or diazepam (2 mg/kg, p.o.),
positive control, and submitted to the behavioral tests. The results show that ursolic acid (10 mg/kg)
elicited an anxiolytic-like effect observed by the increased total time in the center and decreased number
of rearings responses in the open ﬁeld test and an increased percentage of entries and total time spent in
the open arms of elevated plus maze, similarly to diazepam. No signiﬁcant effects of ursolic acid were
shown in the light/dark box and marble burying test. These data indicate that ursolic acid exhibits
anxiolytic-like effects in the open ﬁeld and elevated plus maze test, but not in the light/dark box and
marble burying test, showing the relevance of testing several behavioral paradigms in the evaluation of
anxiolytic-like actions. Of note, the results extend the understanding on the effects of ursolic acid in the
central nervous system and suggest that it may be a novel approach for the management of anxiety-
related disorders.
& 2015 Published by Elsevier B.V.
1. Introduction
Ursolic acid ((3β)-3-hydroxyurs-12-en-28-oic acid, Fig. 1) is a
pentacyclic triterpenoid widely found in different medicinal herbs
and in several foods, thereby constituting an integral part of
human diets. Ursolic acid possesses many biological effects,
including antitumor, anti-inﬂammatory and antioxidant activities
(Alqahtani et al., 2013; Lee et al., 2008; Sultana and Saify, 2012).
Moreover, its administration is able to produce neuropharmaco-
logical effects in rodents including improvement in cognitive
deﬁcits elicited by different insults (Lu et al., 2011; Wang et al.,
2011; Wu et al., 2013), neuroprotective (Li et al., 2013), antinoci-
ceptive (Verano et al., 2013) and antidepressant-like effects in the
tail suspension test and forced swimming test (Colla et al., 2014;
Machado et al., 2012b). However, the anxiolytic proﬁle of this
compound is not demonstrated so far.
Anxiety disorders are the most common psychiatric condition
in the primary care practitioners, with a prevalence estimated in
13% (Kessler et al., 2005). This disorder causes signiﬁcant costs in
terms of healthcare use, disability, loss of productive and quality of
life of patients (Combs and Markman, 2014). Furthermore, suicide
risk increases with acute and chronic anxiety disorders (Khan
et al., 2002). The medication side effects are a major limitation to
adherence and successful treatment of the patients and draw
attention to the need for new treatment alternatives (Thronson
and Pagalilauan, 2014).
Different behavioral tasks are used for the study of the
neurobiological basis of anxiety and in the screening for novel
anxiolytic compounds. The open ﬁeld test, the elevated plus maze
test, the light/dark box test and the marble burying test are the
main tests used to evaluate anxiolytic responses in mice and rats
(Ennaceur, 2014; Kedia and Chattarji, 2014; Walf and Frye, 2007).
The ﬁrst-line pharmacologic treatment of anxiety disorders
aims to prevent future symptoms, and consist in the use of
antidepressants that inhibit the reuptake of serotonin, norepi-
nephrine or both (Combs and Markman, 2014; Thronson and
Pagalilauan, 2014). Ursolic acid elicits an antidepressant-like effect
in mice dependent on the activation of monoaminergic systems,
due to its ability to inhibit the reuptake of monoamines (Colla
et al., 2014; Machado et al., 2012b). Therefore, this study aims to
investigate the possible anxiolytic-like activity of ursolic acid
administration in different behavioral tasks: open ﬁeld, elevated
plus maze, light/dark box, and marble burying test, in mice.
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2. Materials and methods
2.1. Animals
Male Swiss mice (40–50 g, 50–60 days old) obtained from the
Central Biothery of Universidade Federal de Santa Catarina (UFSC)
were used. The animals were housed in groups of 15 animals per
plastic cage under controlled conditions of light (12:12 h, lights on
at 07:00 h) and temperature (20–22 1C) with free access to water
and food. Mice were allowed to acclimatize to the holding room
for 24 h before the behavioral procedure. All manipulations were
conducted in the light phase (n¼8 animals per group). All
procedures were performed in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory
Animals and approved by the Ethics Committee of the Institution.
2.2. Drugs and treatment
Ursolic acid (C30H48O3, Sigma Chemical Co, St. Louis, MO, USA) was
dissolved in distilled water with 10% of Tween 80, and diazepam
(positive control) (Produtos Roche Químicos e Farmacêuticos S.A., Rio
de Janeiro, Brazil) was dissolved in distilled water. The control group
received distilled water. Ursolic acid in the doses of 0.1, 1 and 10mg/
kg, or diazepam in the dose of 2 mg/kg, was administered orally 1 h
before the behavioral tests in a constant volume of 10ml/kg body
weight. Independent groups of mice were tested in each test.
2.3. Open ﬁeld test
The open ﬁeld test besides providing measures of exploratory
behavior is a valid initial screening test for anxiety-related
behavior in rodents (Deacon et al., 2002). In this test, mice were
individually submitted to the circular open ﬁeld, an arena of 30 cm
of diameter with the ﬂoor divided into 8 spaces. The number of
squares crossed with the four paws was registered during a 6 min
period and was considered as a parameter of locomotor activity.
The increased time in the central zone of the apparatus, decreased
number of rearings and groomings (washing of the coat) were
considered as an anxiolytic-like effect (Kalueff et al., 2007a;
Machado et al., 2012a). The ﬂoor of the apparatus was cleaned
with 10% ethanol between tests.
2.4. Elevated plus maze test
Elevated plus maze test is the most employed test to evaluate
anxiolytic activity of drugs (Walf and Frye, 2007). The maze
consists of a central platform (66 cm), and two open arms
(306 cm) aligned perpendicularly to two closed arms
(30 cm6 cm16 cm). The open arms had 1 cm high plexiglass
rim to prevent fall. The entire apparatus was elevated to a height
of 50 cm above the ﬂoor. Mice were individually placed into the
central square of the maze, facing between open arm and closed
arm and their spontaneous behavior was recorded for 5 min. The
percentage of the total entries and the total time spent in the open
arms were measured. Increased entries into the open arms and
increased time spent in the open arms were considered indices of
anxiolytic proﬁle (Budzynska et al., 2013; Lapmanee et al., 2013).
The ﬂoor of the elevated plus maze apparatus was cleaned with
10% ethanol between tests.
2.5. Light/dark box test
In this test the exploratory activity is inﬂuenced by hazard and
risk avoidance (Bourin and Hascoet, 2003). The apparatus consists
in a box with one-third for the dark compartment and two thirds
for the light compartment interconnected with an exterior size of
462030 cm. The test is based on the observation that
although rodents naturally tend to explore a novel environment,
the safe area to mice is the small dark compartment and the
aversive area is the illuminated compartment (Bourin and Hascoet,
2003). Mice were placed in the light area and the latency time for
the ﬁrst entry into the dark compartment as well as the total time
spent in the light compartment was registered for 5 min. These
parameters were used to infer about anxiolytic behavioral
responses. Anxiolytic drugs increase the latency time to entry in
the dark area and the total time in the light area (Bourin and
Hascoet, 2003; Costall et al., 1989; Imaizumi et al., 1994). The ﬂoor
of the light/dark box apparatus was cleaned with 10% ethanol
between tests.
2.6. Marble burying test
The marble burying test is supposed to reﬂect repetitive and
perseverative behavior, likely related to compulsions and/or anxi-
ety disorders (Kedia and Chattarji, 2014). A cage (17.510
5.5 cm) was ﬁlled approximately 5 cm deep with husk bedding
material that was evenly distributed into a ﬂat surface across the
whole cage. Twenty glass marbles (1.4 cm in diameter) were then
spaced evenly in a 45 grid on the surface of the bedding. During
the testing phase each mouse was placed in the cage and allowed
to explore it for 20 min. At the end of the test, mice were removed
from the cage and the number of marbles buried with bedding up
to 2/3 of their depth was counted (Kedia and Chattarji, 2014).
Rodents use bedding material to bury harmless objects and the
inhibition of object burying is considered as an anxiolytic proﬁle
(Albelda and Joel, 2012).
2.7. Statistical analysis
All experimental results are given as mean7S.E.M. Comparisons
between experimental and control groups were performed by one-
way ANOVA followed by Newman–Keuls posthoc test when appro-
priate. A value of Po0.05 was considered to be signiﬁcant.
3. Results
3.1. Effect of ursolic acid in the open ﬁeld test
The results presented in Fig. 2A show that neither ursolic acid
nor diazepam administrations induced changes in the sponta-
neous locomotion in mice. However, the total time spent in the
center of the apparatus and the total number of the rearing were
reduced by ursolic acid (10 mg/kg), in a way similar to diazepam
(2 mg/kg, positive control) (Fig. 2B and C, respectively). The
number of groomings was decreased only by diazepam adminis-
tration (Fig. 2D). The one-way ANOVA revealed no signiﬁcant
effects of treatment on the number of crossings [F(4,35)¼1.95,
P¼0.12]. On the other hand, signiﬁcant effects of treatment were
Fig. 1. Chemical structure of ursolic acid.
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shown on the total time spent in the center [F(4,35)¼3.94,
Po0.01], number of rearings [F(4,35)¼6.48, Po0.01] and groom-
ings [F(4,35)¼4.62, Po0.01] in the open ﬁeld test.
3.2. Effect of ursolic acid in the elevated plus maze
The results depicted in Fig. 3 show that the acute treatment
with ursolic acid (10 mg/kg) as well as diazepam (2 mg/kg) was
able to increase the percentage of open arms entries (A) and total
time spent in the open arms (B) of the elevated plus maze. The
one-way ANOVA showed a signiﬁcant effect of treatment [F
(4,35)¼3.16, Po0.05] on the open arms entries and a signiﬁcant
effect of treatment [F(4,35)¼4.76, Po0.05] on the total time spent
in the open arms of the elevated plus maze.
3.3. Effect of ursolic acid in the light/dark box
Fig. 4 shows that the treatment with ursolic acid was not able to
alter the parameters analyzed in the light/dark box. The positive
control, diazepam (2 mg/kg), increased the latency for the ﬁrst entry in
the dark area (A) and the total time spent in the light area of the
apparatus (B). The one-way ANOVA showed a signiﬁcant effect of
treatment [F(4,35)¼3.50, Po0.05] on the latency time to enter in the
dark area and a signiﬁcant effect of treatment [F(4,35)¼3.62, Po0.05]
on the total time spent in light area of the light/dark box.
3.4. Effect of ursolic acid in the marble burying test
Fig. 5 shows that the treatment with ursolic acid was not able
to alter the number of marbles buried in the marble burying test.
Conversely, the positive control diazepam (2 mg/kg) decreased the
number of marbles buried in this test. The one-way ANOVA
showed a signiﬁcant effect of treatment [F(4,35)¼3.65, Po0.05]
on the total number of marbles buried in the marble burying test.
4. Discussion
Anxiety disorders are severe psychiatric conditions that affect
performance in daily tasks and represent a high cost to public health
(Campos et al., 2013; Combs and Markman, 2014). Given the costs in
Fig. 2. Effect of treatment with ursolic acid (UA, 0.1, 1 and 10 mg/kg) or diazepam (DZP, 2 mg/kg) in the number of crossings (A), total time spent in the center (B), number of
rearings (C), and number of groomings (D) in the open ﬁeld test. Each column represents the mean7S.E.M (n¼8). *Po0.05 and **Po0.01 when compared with vehicle-
treated control (one-way ANOVA followed by Newman–Keuls posthoc test).
Fig. 3. Effect of treatment with ursolic acid (UA, 0.1, 1 and 10 mg/kg) or diazepam (DZP, 2 mg/kg) in the percentage of open arms entries (A) and total time spent in the open
arms (B) in the elevated plus maze test. Each column represents the mean7S.E.M (n¼8). *Po0.05 compared with the vehicle-treated control (one-way ANOVA followed by
Newman–Keuls posthoc test).
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terms of debilitation and associated ﬁnancial burden, and increased
risk of suicide, the search for new and effective treatment of anxiety
disorders is imperative (Combs and Markman, 2014). Despite their
drawbacks, animal models are invaluable tools for investigation of the
neurobiology of anxiety-related disorders (Campos et al., 2013).
Among the available tests to assess anxiety-like behavior, the open
ﬁeld test, the elevated plus maze, and the light/dark box are the most
commonly used (Kliethermes, 2005). In this study, we evaluated the
possible anxiolytic-like effect of ursolic acid administration in different
behavioral paradigms, the open ﬁeld test, elevated plus maze, light/
dark box and marble burying test. Our results demonstrate that acute
administration of ursolic acid (10 mg/kg) produced an anxiolytic-like
effect in the open ﬁeld test and elevated plus maze. Interestingly, the
effective anxiolytic dose is the same one that presents other neuro-
pharmacological effects such as antidepressant-like effect in the forced
swimming test (Machado et al., 2012b), and antioxidant and anti-
inﬂammatory properties in mice (Lu et al., 2007, 2010). Otherwise,
studies regarding its antitumor property show that higher doses of
this compound (50–200 mg/kg) are necessary to elicit antitumoral
action (De Angel et al., 2010; Shanmugam et al., 2011; Shih et al.,
2013).
The open ﬁeld test is a widely used procedure for examining
the behavioral effects of drugs in locomotor activity and anxious
behavior (Choleris et al., 2001; Rodrigues et al., 1996). To evaluate
the effect of treatments (ursolic acid and diazepam) in the
locomotor activity, the number of crossings was measured in the
open ﬁeld test. Ursolic acid and diazepam caused no alterations in
the spontaneous locomotion of animals, ruling out the possibility
that psychostimulant effect may account for the observed beha-
vioral responses indicative of anxiolytic action in the tests
employed. Besides the locomotor parameter, the open ﬁeld test
allows making inferences about anxious behavior, since anxiolytic
compounds lead to an increase in the total time spent in the center
of apparatus, and a decrease in the number of rearings and
groomings (Costa et al., 2014; Kalueff et al., 2007a; Lakshmi-
pathy Prabhu et al., 2012; Machado et al., 2012a). Our results
showed that the ursolic acid administration, at dose of 10 mg/kg,
similar to diazepam (2 mg/kg), was able to produce an increase in
the total time spent in the center of open ﬁeld and a reduction in
the number of rearings, suggesting an anxiolytic-like effect of the
ursolic acid administration. The number of groomings was
reduced only in the diazepam group. In fact, the number of
grooming was reported to be reduced by anxiolytic drugs; how-
ever, grooming behavior has been proposed as a parameter related
more speciﬁcally with obsessive–compulsive disorder than uncon-
ditioned anxiety (Ting and Feng, 2011; Yang and Lu, 2011).
To reinforce the notion that ursolic acid exhibits anxiolytic
properties, we tested its effect in the elevated plus maze that is a
well-established and the most used test to detect anxiolytic/
anxiety-like effect (Hogg, 1996; Walf and Frye, 2007). Similar to
the open ﬁeld test, the elevated plus maze is based on the natural
conﬂict between the drive to explore a new environment and the
tendency to avoid a potentially dangerous area (Ramos, 2008). The
most classical indices of anxiolytic-like behavior in elevated plus
maze test are the increased percentage in open arms entries and
total time spent in the open arms (Jindal et al., 2013; Rodgers and
Dalvi, 1997). Our results demonstrate that the acute administration
of ursolic acid, at dose of 10 mg/kg, the same dose that presented
anxiolytic-like behavior in the open ﬁeld test, presents an
anxiolytic-like effect in the elevated plus maze, since it increased
the percentage of open arms entries and the total time spent in the
open arms, similar to the result produced by diazepam, used as a
reference drug. The elevated plus maze can be considered a very
valuable tool in drug screening and in the study of the neurobiol-
ogy of anxiety (Rodgers and Dalvi, 1997), and our results
strengthen the notion that ursolic acid administration may elicit
an anxiolytic-like effect in mice.
The light/dark box is a test based on the innate aversion of
rodents to places with bright light. It generates an inherent
conﬂict between the exploratory drive of rodents and their
avoidance of the lit compartment (Campos et al., 2013). In our
study, no dose of ursolic acid was able to induce anxiolytic
behavior in this test. Conversely, diazepam administration
increased the latency to ﬁrst entry in the dark side and the total
time spent in the light compartment. The literature data reported
that the administration of anxiolytics increases the latency to
enter in the less aversive side of the box and increases the time
spent in the lit compartment, more aversive side (Kliethermes,
2005). Indeed, benzodiazepines are reliably detected in this
behavioral paradigm. On the contrary, antidepressant compounds,
especially those that act on the serotonergic system, have been
shown to elicit a mild response or even no response in the light/
dark box in mice (Bourin and Hascoet, 2003). Interesting, ursolic
Fig. 4. Effect of treatment with ursolic acid (UA, 0.1, 1 and 10 mg/kg) or diazepam (DZP, 2 mg/kg) in the latency time for the ﬁrst entry in the dark area (A) and total time
spent in the light area (B) in the light/dark box test. Each column represents the mean7S.E.M (n¼8). *Po0.05 compared with the vehicle-treated control (one-way ANOVA
followed by Newman–Keuls posthoc test).
Fig. 5. Effect of treatment with ursolic acid (UA, 0.1, 1 and 10 mg/kg) or diazepam (DZP,
2 mg/kg) in the number of the marbles buried in the marble burying
test. Each column represents the mean7S.E.M (n¼8). nnPo0.01 compared with the
vehicle-treated control (one-way ANOVA followed by Newman–Keuls posthoc test).
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acid was previously reported to exert an antidepressant-like effect
by a serotonergic-mediated mechanism (Colla et al., 2014), a
ﬁnding that could explain the lack of response of ursolic acid in
the light/dark box. Moreover, ursolic acid exhibited a signiﬁcant
inhibition of monoamine oxidase B (Kim et al., 2012), and
literature shows that monoamine oxidase B inhibitors, such as
selegiline, exert no anxiolytic-like effect in this test (De Angelis
and Furlan, 2000).
Rodents use bedding material to bury noxious as well as harmless
objects and the inhibition of object burying is suggested as a screening
test for anxiolytic activity (Albelda and Joel, 2012). In our study, ursolic
acid administration did not produce anxiolytic proﬁle in the marble
burying test, since it was not able to cause a decrease in the marble
buried. Interestingly, ursolic acid administration displayed anxiolytic
effects in the open ﬁeld test and elevated plus maze, but not in the
light/dark box or marble burying test. Notably, marble burying test has
been suggested as a more speciﬁc test to study obsessive–compulsive
disorder than generalized anxiety (Albelda and Joel, 2012; Kalueff
et al., 2007b). Furthermore, ursolic acid besides not causing signiﬁcant
effects in marble burying test produced no change in the number of
groomings in the open ﬁeld test, a parameter that has been also
proposed to investigate obsessive–compulsive disorder-related beha-
vior (Fineberg et al., 2011; Graybiel and Saka, 2002). Despite open ﬁeld
test, elevated plus maze, light/dark box, and marble burying test are
supposed to evaluate anxiety-like behavior in rodents; it is feasible
that these behavioral tests detect different aspects of the multifaceted
and complex nature of anxiety, since the neurobiological mechanisms
underlying the behavioral responses in each test may be different
(Albelda and Joel, 2012; Gavioli et al., 2007; Kalueff et al., 2007b; Kedia
and Chattarji, 2014). In line with this, our study shows the relevance of
testing several behavioral paradigms in the evaluation of anxiolytic-
like actions.
Altogether, the results of the present study demonstrate for the
ﬁrst time the anxiolytic-like effect of ursolic acid administration in
the open ﬁeld test and elevated plus maze, behavioral tests
broadly used for the screening of anxiolytic compounds. Preclini-
cal studies show that not only benzodiazepines, but also anti-
depressants are able to reduce the typical anxiety-like behaviors in
rodents in these behavioral paradigms (Bourin and Hascoet, 2003;
Choleris et al., 2001; Jindal et al., 2013). Consistently, ursolic acid, a
compound with safe pharmacological proﬁle (Aggarwal et al.,
2004), has been shown by our group to exert antidepressant-like
effect (Colla et al., 2014; Machado et al., 2012b). The diagnosis of
depression is often associated with the presence of others dis-
orders, particularly with anxiety disorders, being the most pre-
valent comorbidity (Brown et al., 2001; Hecht et al., 1990), and
selective serotonin reuptake inhibitors and serotonin–norepi-
nephrine reuptake inhibitors effectively prevent anxiety symp-
toms, reduce the risk for relapse, and have a better safety proﬁle in
comparison with benzodiazepines, which confer no long-term
preventive beneﬁt (Baldwin et al., 2011; Thronson and
Pagalilauan, 2014). Considering the high anxiety/depression
comorbidity, the need to develop more efﬁcacious pharmacologi-
cal approaches to the management of this condition (Baldwin
et al., 2011), the previously reported antidepressant-like effect of
ursolic acid and its anxiolytic-like effect demonstrated in this work
suggest that the pharmacological action of ursolic acid may offer a
novel therapeutic strategy for the treatment of comorbidity
depression/anxiety.
5. Conclusions
In summary, the results of this study show for the ﬁrst time
that the acute oral administration of ursolic acid elicits an
anxiolytic-like effect in widely and well-established tests to
evaluate generalized anxiety in mice, the open ﬁeld test and
elevated plus maze. The results suggest that it may be a novel
approach for the management of anxiety-related disorders.
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